SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corp. (NASDAQ:BSDM) announced today that a team of researchers headed by Professor Rolf D. Issels will be announcing at the upcoming annual American Society of Clinical Oncology (ASCO) conference that a Phase III clinical study is underway involving the combined use of hyperthermia therapy and chemotherapy in treating patients with pancreatic cancer. This announcement follows the successful conclusion of a Phase II clinical trial conducted in Munich, Germany using a combination of hyperthermia therapy and chemotherapy to treat patients with pancreatic cancer. All hyperthermia treatments used for this study will be delivered using BSD-2000 hyperthermia systems. The ASCO conference held in Chicago, Illinois will run May 30 through June 3.
